POROS™ MabCapture™ A Select Resin

Catalog number: A26456

Applied Biosystems™  Related applications: Chromatography

Error loading your content!

  Catalog number
Select a plan
Unit size
Price ({{currency}}) Your price ({{currency}}) Availability Qty
{{product.sku}} {{product.sku}}
also known as {{product.formattedSku}} 
{{subscriptionDetails.selectedRatePlan.billingPeriod}} {{subscriptionDetails.selectedRatePlan.billingPeriod}} {{product.availability.message}}
Pro add-ons

Your on-site stock

›› {{supplyCenter.scName}}({{scProduct.stockOnHand}} In stock)
›› {{supplyCenter.scName}}(Out of stock)
›› {{supplyCenter.scName}}
This item is not currently available on-site. Depending on your Supply Center settings you may be able to add the item to cart above else use the Order Non-Stocked Items' tab on the Supply Center home page.
Back to top


POROS™ MabCapture™ A Select is a new high-throughput, lower-priced Protein A chromatography resin, combining past improvements to MabCapture A with our own Protein A ligand, enabling the same high-throughput purification performance at a significant reduction in price over most Protein A chromatography resins . These advances provide a monoclonal antibody purification resin that demonstrates high dynamic binding performance at low flow rates and maintains superior binding capacity at high linear velocities where other chromatography media products cannot operate.

With POROS MabCapture A affinity chromatography resin you can:
• Obtain the highest dynamic binding capacity for monoclonal antibodies vs. conventional agarose- or silica-based Protein A resins
• Maintain high dynamic binding capacity at flow rates over 700 cm/hr
• Design processes with greater flexibility (shorter bed heights, faster flow rates, or both) due to the improvements made to the antibody binding efficiency
• Clean and sanitize with standard sodium hydroxide agents used for other chromatography products
• Recognize major increases to process productivity and reduce the downstream bottleneck

The development of humanized monoclonal antibodies has continued to fuel the growth of the biotherapeutic market. Addressing the therapeutic demand for monoclonal antibodies has led to major improvements to the cell-based expression systems that are used to manufacture these proteins. Consequently, these improvements have moved the processing bottleneck from upstream cell expression to downstream purification. Protein A chromatography, which is used as the primary capture chromatography step in most antibody process platforms, is generally regarded as the major process bottleneck due to the slow flow rates and long residence times required for the effective operation of conventional Protein A chromatography media. The introduction of POROS MabCapture chromatography media was aimed at cracking open the downstream bottleneck and providing the capacity, efficiency, and flexibility needed to make improvements to the downstream purification platform, resulting in major increases to process productivity and antibody manufacturing.

Contents & storage

Store in refrigerator (2–8°C).


Manuals & protocols